---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-065603"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T08:34:47.684551+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IN8bio reports Q1 2025 net loss of $5.6M; INB-100 shows 100% AML relapse-free at 20.1 months

## Summary
- Net loss $5.6M ($0.07/sh) vs. $8.6M ($0.20/sh) prior year; cash $11.9M as of March 31, 2025.
- Phase 1 INB-100 data: 100% AML patients relapse-free at median 20.1 months follow-up; no CRS/ICANs.
- Presented INB-600 TCE platform at AACR 2025 showing picomolar potency and minimal cytokine release.
- Upcoming oral presentation at ASCO 2025 for INB-200 in glioblastoma (May 30, 2025).
- Raised ~$4.1M net from ATM and warrant exercises in Q1 2025; additional $1.9M gross in April 2025.

## SEC filing metadata
- accession: 0000950170-25-065603
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000095017025065603/0000950170-25-065603-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000095017025065603/inab-20250507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-065603
- JSON: https://secwatch.observer/filing/0000950170-25-065603.json
- Plain text: https://secwatch.observer/filing/0000950170-25-065603.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.